Nuvation Bio Inc.
NUVB evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for NUVB—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · NUVB
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, with lead programs including taletrectinib for ROS1-positive non-small cell lung cancer and safusidenib for IDH1-mutant gliomas.
Key risk: Clinical trial failure risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$2.34B
Cash Runway
46.1 moLead Asset
ibtrozi (Approved)Next Catalyst
Phase2_Start · Mar 1, 2027Financial data as of Jun 30, 2026.
Tracking 5 pipeline candidates · 13 clinical trials · 6 catalysts for Nuvation Bio Inc..
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, with lead programs including taletrectinib for ROS1-positive non-small cell lung cancer and safusidenib for IDH1-mutant gliomas.
- Cash & equivalents of $258.6M as of 2026-06-30 [sec].
- Total revenue of $31.7M as of 2026-06-30 [sec].
- Net loss of -$62.8M as of 2026-06-30 [sec].
- Shareholders' equity of $305.7M and total debt of $248.5M as of 2026-06-30 [sec].
- Accumulated deficit of $1,110.0M as of 2026-03-31 [sec_mda].
What works
- Taletrectinib has received regulatory submissions in Japan and positive Phase 2 data published in the Journal of Clinical Oncology [sec_mda · as of 2025-05-07].
- The company has an exclusive license agreement with Eisai for taletrectinib in Europe and additional countries, potentially expanding market reach [sec_mda · as of 2026-03-02].
- Cash and marketable securities of $533.7M as of March 31, 2026, provide a substantial runway for ongoing operations [sec_mda · as of 2026-05-04].
What to weigh
- The company has an accumulated deficit of $1,110.0M as of March 31, 2026, reflecting significant historical losses [sec_mda · as of 2026-05-04].
- Net loss of -$62.8M for the quarter ended June 30, 2026, indicates ongoing cash burn [sec].
- Total debt of $248.5M as of June 30, 2026, adds financial leverage and interest obligations [sec].
- The company expects to incur substantial expenses for development and commercialization, with no guarantee of future profitability [sec_mda · as of 2026-03-02].
From the filings
Quoted directly from source documents.
Cash and marketable securities as of March 31, 2026
“As of March 31, 2026, we had $533.7 million in cash, cash equivalents and marketable securities and an accumulated deficit of $1,110.0 million.”
SEC MD&A · May 4, 2026
Taletrectinib Phase 2 data publication
“In April 2025, pooled data from our pivotal Phase 2 TRUST-I and TRUST-II studies of taletrectinib was published in the Journal of Clinical Oncology (Perol, et al., 2024).”
SEC MD&A · May 7, 2025
Eisai license agreement for taletrectinib
“In January 2026, we announced entry into an exclusive license agreement for taletrectinib in Europe and additional countries with Eisai.”
SEC MD&A · March 2, 2026
Accumulated deficit as of December 31, 2025
“As of December 31, 2025, we had $529.2 million in cash, cash equivalents and marketable securities and an accumulated deficit of $1,115.4 million.”
SEC MD&A · March 2, 2026
Catalyst timeline
- 2027-03-01 · Phase2_Start — Phase 2 Start: A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine i — Initiation of a Phase 2 trial for safusidenib in IDH1-mutant glioma, a key clinical milestone.
- 2030-09-01 · Phase3_Topline · taletrectinib — Phase 3 Topline: A Phase 3 Multicenter Open-label Study of Taletrectinib Versus a Standard of Care ROS1-Tyrosine Kina — Topline results from a Phase 3 trial comparing taletrectinib to standard of care in ROS1+ NSCLC.
- 2030-12-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine i — Topline results from a Phase 3 trial for safusidenib in IDH1-mutant glioma.
- 2032-03-01 · Phase3_Topline — Phase 3 Topline: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy — Topline results from a Phase 3 randomized trial for an undisclosed candidate.
- 2033-06-03 · Patent_Expiry · IBTROZI — Patent/Exclusivity Expiry: IBTROZI — Expiry of patent or exclusivity for IBTROZI, potentially opening to generic competition.
- 2033-08-30 · Phase3_Topline · taletrectinib — Phase 3 Topline: A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With — Topline results from a Phase 3 double-blind trial of taletrectinib versus placebo.
Risks & what to watch (4)›
Key risks
- Clinical trial failure risk — Phase 2 and 3 trials for safusidenib and taletrectinib may fail to meet endpoints, leading to regulatory setbacks [sec_mda].
- Substantial accumulated deficit — Accumulated deficit of $1,110.0M as of March 31, 2026, with ongoing net losses, indicating no near-term profitability [sec_mda].
- Dependence on future funding — The company may need additional capital to complete development, and failure to raise funds could delay or reduce programs [sec_mda].
- Competitive oncology landscape — Taletrectinib and safusidenib face competition from other ROS1 and IDH1 inhibitors in development or on market [sec_mda].
What to watch
- Phase 2 start for safusidenib in IDH1-mutant glioma expected in March 2027 [catalyst].
- Phase 3 topline data for taletrectinib in ROS1+ NSCLC expected in September 2030 [catalyst].
- Phase 3 topline data for safusidenib in IDH1-mutant glioma expected in December 2030 [catalyst].
- Patent expiry for IBTROZI in June 2033, which may impact future revenue [catalyst].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Nuvation Bio Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Nuvation Bio Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
46.1 months
D/E 1.93
Lead: Approved
5 candidates
6 upcoming, next in ~183d
1 buy · 7 sells (180d)
Runway
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
232
Total value held
$859.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 51,989,593 | $223.0M |
| blackrock, inc. | 25,100,374 | $107.7M |
| vanguard capital management llc | 23,252,396 | $99.8M |
| omega fund management, llc | 8,081,089 | $34.7M |
| laurion capital management lp | 7,822,638 | $33.6M |
| state street corp | 6,784,927 | $29.1M |
| geode capital management, llc | 5,863,654 | $25.2M |
| bank of america corp /de/ | 3,219,826 | $13.8M |
| redmile group, llc | 3,153,256 | $13.5M |
| tang capital management llc | 3,149,557 | $13.5M |
Showing top 10 of 232 institutional holders of Nuvation Bio Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 24.1%
- Days to cover
- 15.1
- Shares short
- 50,622,584
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
NUVB short interestGovernance
Frequently asked questions
What is the AI investment thesis for Nuvation Bio Inc.?
Nuvation Bio Inc. is a clinical-stage biopharmaceutical company focused on developing novel oncology therapies, with lead programs including taletrectinib for ROS1-positive non-small cell lung cancer and safusidenib for IDH1-mutant gliomas.
What is Nuvation Bio Inc.'s lead drug candidate?
Nuvation Bio Inc.'s most advanced tracked candidate is ibtrozi (Approved) for Adult patients with locally advanced or metastatic ROS1-positive ("ROS1+") non-small cell lung cancer ("NSCLC").
What is Nuvation Bio Inc.'s next catalyst?
Nuvation Bio Inc.'s next tracked catalyst is a Phase2_Start event — "Phase 2 Start: A Phase 2, Multicenter, Clinical Study to Evaluate the Efficacy and Safety of Safusidenib Erbumine i" — expected March 1, 2027.
Who is the CEO of Nuvation Bio Inc.?
Dr. David T. Hung M.D. is the chief executive officer of Nuvation Bio Inc. (NUVB).
Where is Nuvation Bio Inc. headquartered?
Nuvation Bio Inc. (NUVB) is headquartered in New York, NY, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.